ESPR
Esperion Therapeutics, Inc.
$3.18
-0.01
(-0.31%)
Mkt Cap
661.15M
Volume
58,424,038
52W Range
1.1-4.18
Sector
Healthcare
Beta
1.06
EPS (TTM)
-0.02
P/E Ratio
-33.64
Revenue (TTM)
418.24M
Rev Growth (5Y)
+12.1%
EPS Growth (5Y)
N/A
Company Description
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 403.13M | 332.31M | 116.33M | 75.47M | 78.45M | 227.55M | 148.36M | 184.47M | 0 | 0 | 0 | 0 |
| Net Income | (22.68M) | (51.74M) | (209.25M) | (233.66M) | (269.11M) | (143.55M) | (97.17M) | (201.81M) | (166.99M) | (74.98M) | (49.78M) | (36.38M) |
| EPS | -0.11 | -0.28 | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 |
| Free Cash Flow | (13.09M) | (23.97M) | (135.49M) | (174.83M) | (263.81M) | (98.55M) | (71.29M) | (148.79M) | (131.32M) | (47.82M) | (38.48M) | (32.89M) |
| FCF / Share | -0.06 | -0.13 | -1.31 | -2.63 | -9.13 | -3.59 | -2.63 | -5.56 | -5.49 | -2.12 | -1.75 | -2.01 |
| Operating CF | (13.09M) | (23.65M) | (135.49M) | (174.83M) | (263.81M) | (85.18M) | (70.34M) | (148.64M) | (131.30M) | (47.73M) | (38.16M) | (32.02M) |
| Total Assets | 465.89M | 343.82M | 205.80M | 247.94M | 381.59M | 353.26M | 214.45M | 143.45M | 277.83M | 245.21M | 295.57M | 143.34M |
| Total Debt | 548.00M | 591.21M | 540.95M | 260.95M | 260.20M | 185.41M | 1.56M | 0 | 1.04M | 2.73M | 4.29M | 4.94M |
| Cash & Equiv | 167.85M | 144.76M | 82.25M | 124.78M | 208.89M | 304.96M | 166.13M | 36.97M | 34.47M | 38.16M | 77.34M | 85.04M |
| Book Value | (301.96M) | (388.72M) | (454.99M) | (323.78M) | (196.94M) | (96.13M) | 19.95M | (598.10M) | 244.69M | 228.60M | 287.26M | 133.55M |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -4.87 | N/A | -0.68 | -0.33 | -0.17 | -0.27 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 80.10M | 168.45M | 87.31M | 82.39M | 65.00M | 69.11M | 51.63M | 73.83M | 137.74M | 32.25M | 33.97M | 25.79M |
| Net Income | (25.20M) | 61.83M | (31.33M) | (12.72M) | (40.45M) | (21.32M) | (29.52M) | (61.92M) | 61.02M | (56.34M) | (41.25M) | (49.94M) |
| EPS | -0.10 | 0.26 | -0.16 | -0.02 | -0.21 | -0.11 | -0.15 | -0.33 | 0.36 | -0.50 | -0.37 | -0.46 |
| Free Cash Flow | (27.91M) | 45.43M | (4.29M) | (31.42M) | (22.63M) | (34.95M) | (35.49M) | (7.28M) | 53.76M | (37.06M) | (19.32M) | (24.75M) |
| FCF / Share | -0.11 | 0.19 | -0.02 | -0.16 | -0.12 | -0.18 | -0.18 | -0.04 | 0.32 | -0.33 | -0.17 | -0.23 |
| Operating CF | (27.72M) | 45.24M | (4.29M) | (31.42M) | (22.63M) | (34.95M) | (35.33M) | (7.21M) | 53.83M | (37.06M) | (19.32M) | (24.75M) |
| Total Assets | 462.53M | 465.89M | 364.02M | 347.08M | 324.03M | 343.82M | 314.11M | 352.32M | 373.06M | 205.80M | 221.31M | 234.63M |
| Total Debt | 543.81M | 548.00M | 600.99M | 598.18M | 297.78M | 297.60M | 268.96M | 269.13M | 548.87M | 540.95M | 301.14M | 285.91M |
| Cash & Equiv | 156.16M | 167.85M | 92.45M | 86.06M | 114.63M | 144.76M | 144.72M | 189.30M | 226.61M | 82.25M | 114.83M | 138.47M |
| Book Value | (307.93M) | (301.96M) | (451.36M) | (433.51M) | (426.21M) | (388.72M) | (370.21M) | (344.22M) | (294.30M) | (454.99M) | (410.00M) | (371.98M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ESPR News
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PFLC, ESPR, LKSB, and MKC
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR)
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders